120 related articles for article (PubMed ID: 32600932)
1. Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy.
Alduailej H; Kanfar S; Bakhit K; Raslan H; Alsaber A; Bashawri L; Aldayel A; Alanezi K
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e560-e568. PubMed ID: 32600932
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia.
Esteban RE; Christianne B; Alvaro A; Demichelis-Gómez R
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):361-367. PubMed ID: 29544762
[TBL] [Abstract][Full Text] [Related]
3. CD20 and Outcome of Childhood Precursor B-cell Acute Lymphoblastic Leukemia: A Meta-analysis.
Ou DY; Luo JM; Ou DL
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e138-42. PubMed ID: 25222059
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Thomas DA; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Ravandi F; Verstovsek S; Jorgensen JL; Bueso-Ramos C; Andreeff M; Pierce S; Garris R; Keating MJ; Cortes J; Kantarjian HM
J Clin Oncol; 2010 Aug; 28(24):3880-9. PubMed ID: 20660823
[TBL] [Abstract][Full Text] [Related]
5. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
6. [Expression of CD20 in B-cell precursor acute lymphoblastic leukemia and its correlation with clinical outcomes].
Chen XX; Yuan LX; Zhang G; Wan CM; Huo WY; Tang X; Ai Y; Wan Z; Zhu YP; Gao J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):658-63. PubMed ID: 25286695
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Thomas DA; O'Brien S; Jorgensen JL; Cortes J; Faderl S; Garcia-Manero G; Verstovsek S; Koller C; Pierce S; Huh Y; Wierda W; Keating MJ; Kantarjian HM
Blood; 2009 Jun; 113(25):6330-7. PubMed ID: 18703706
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
Maury S; Chevret S; Thomas X; Heim D; Leguay T; Huguet F; Chevallier P; Hunault M; Boissel N; Escoffre-Barbe M; Hess U; Vey N; Pignon JM; Braun T; Marolleau JP; Cahn JY; Chalandon Y; Lhéritier V; Beldjord K; Béné MC; Ifrah N; Dombret H;
N Engl J Med; 2016 Sep; 375(11):1044-53. PubMed ID: 27626518
[TBL] [Abstract][Full Text] [Related]
9. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
Maury S; Huguet F; Leguay T; Lacombe F; Maynadié M; Girard S; de Labarthe A; Kuhlein E; Raffoux E; Thomas X; Chevallier P; Buzyn A; Delannoy A; Chalandon Y; Vernant JP; Rousselot P; Macintyre E; Ifrah N; Dombret H; Béné MC;
Haematologica; 2010 Feb; 95(2):324-8. PubMed ID: 19773266
[TBL] [Abstract][Full Text] [Related]
10. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Dworzak MN; Schumich A; Printz D; Pötschger U; Husak Z; Attarbaschi A; Basso G; Gaipa G; Ratei R; Mann G; Gadner H
Blood; 2008 Nov; 112(10):3982-8. PubMed ID: 18780832
[TBL] [Abstract][Full Text] [Related]
11. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
Ceppi F; Weitzman S; Woessmann W; Davies K; Lassaletta A; Reismüller B; Mellgren K; Uyttebroeck A; Maia I; Abdullah S; Miakova N; Glaser D; Cohn R; Abla O; Attarbaschi A; Alexander S
Am J Hematol; 2016 May; 91(5):486-91. PubMed ID: 26872652
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20
Luo C; Wu G; Huang X; Ma Y; Zhang Y; Song Q; Xie M; Sun Y; Huang Y; Huang Z; Hou Y; Xu S; Chen J; Li X
Sci Rep; 2021 Feb; 11(1):3255. PubMed ID: 33547368
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow infiltration of CD20-negative follicular lymphoma after rituximab therapy: a histological mimicker of hematogones and B-cell acute lymphoblastic leukemia/lymphoma.
Matsuda I; Hirota S
Int J Clin Exp Pathol; 2015; 8(8):9737-41. PubMed ID: 26464748
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of CD20 Expression in Children with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
Wang Y; Xue YJ; Jia YP; Zuo YX; Lu AD; Zhang LP
Acta Haematol; 2023; 146(5):349-357. PubMed ID: 37212472
[TBL] [Abstract][Full Text] [Related]
16. Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
Bommannan K; Arumugam JR; Radhakrishnan V; Sundersingh S
Br J Haematol; 2024 Apr; 204(4):1367-1374. PubMed ID: 38444113
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features and survival analysis of patients with CD20 positive adult B-lineage acute lymphoblastic leukemia].
Ma J; Sun H; Chen SM; Liu LX; Chen SQ; Liu YF; Xie XS; Meng XL; Deng M; Zhang QT; Li T
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):477-81. PubMed ID: 20416193
[TBL] [Abstract][Full Text] [Related]
18. [CD20 Expression in Adult Patients with B-lineage Acute Lymphoblastic Leukemia and Its Prognostic Significance].
Zhou J; Wang J; Liu H; Zheng HF; Ma L; Wang PF; Yan S; Fu CC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):619-22. PubMed ID: 26117004
[TBL] [Abstract][Full Text] [Related]
19. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study.
Baek DW; Park HS; Sohn SK; Kim DY; Kim I; Ahn JS; Do YR; Lee SR; Eom HS; Lee WS; Kim SH; Lee HS; Lee YJ; Moon JH; Lee JH;
Korean J Intern Med; 2023 Sep; 38(5):734-746. PubMed ID: 37334511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]